{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:00:32Z","timestamp":1786118432044,"version":"build-2736575974"},"reference-count":36,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: NTRK gene fusions are established oncogenic drivers in a diverse spectrum of mesenchymal neoplasms. Although classically described in pediatric entities, NTRK-rearranged sarcomas also occur in adults, where their clinicopathologic features, genomic context, and response to TRK inhibition are less well characterized. Methods: We retrospectively queried a national referral genomics database to identify sarcomas in patients &gt;18 years harboring pathogenic NTRK1, NTRK2, or NTRK3 fusions. Gastrointestinal stromal tumors, duplicate specimens, and cases lacking digitized hematoxylin and eosin slides were excluded. Fusions were identified by whole-transcriptome sequencing, co-occurring genomic alterations by exome-based sequencing, and real-world survival and time on TRK inhibitor therapy were derived from linked insurance claims data; fusion-negative sarcomas and NTRK-rearranged non-sarcoma tumors from the same database served as comparison cohorts. Results: Among 13,040 profiled sarcomas, 19 adult tumors with pathogenic NTRK fusions were identified (median age, 43 years; range, 21\u201377), most of which were high grade (68%) and advanced stage (63% stage IV). Histology was heterogeneous, including spindle cell sarcoma (53%), pleomorphic sarcoma (21%), and tumors corresponding to defined entities such as NF1-associated malignant peripheral nerve sheath tumor and MDM2-amplified dedifferentiated liposarcoma (11% each). NTRK1 and NTRK3 fusions were equally frequent (9 cases each); fusion partners were diverse, with TPM3 (n = 5), EML4 (n = 2), and TFG (n = 2) recurrent and other partners non-recurrent. Additional genomic alterations were common and heterogeneous (72%), including high genome-wide loss of heterozygosity and infrequent but recurrent alterations involving the TERT promoter, NF1, and RB1. All evaluable tumors showed transcriptional activation of the NTRK fusion and increased MAPK pathway activity compared with fusion-negative sarcomas. Nine patients received TRK inhibitors; median time on larotrectinib was 12.5 months, similar to that observed in NTRK-rearranged non-sarcoma tumors, but treatment duration was variable. Conclusions: Adult sarcomas harboring NTRK fusions are rare, morphologically heterogeneous, and biologically diverse. NTRK fusion status alone may not fully capture oncogenic dependence and should be interpreted within the broader clinicopathologic and genomic context.<\/jats:p>","DOI":"10.3390\/cancers18152528","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T15:52:30Z","timestamp":1786031550000},"page":"2528","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adult Sarcomas with NTRK Fusions: Clinicopathologic and Genomic Heterogeneity"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4387-5167","authenticated-orcid":false,"given":"Michael","family":"Schwartz","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA"},{"name":"Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4136-755X","authenticated-orcid":false,"given":"Kieran","family":"Sweeney","sequence":"additional","affiliation":[{"name":"Caris Life Sciences, Phoenix, AZ 85040, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0982-4607","authenticated-orcid":false,"given":"Steven C.","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Virginia School of Medicine, Charlottesville, VA 22908, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kartik","family":"Angara","sequence":"additional","affiliation":[{"name":"Caris Life Sciences, Phoenix, AZ 85040, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Atrium Health Wake Forest Baptist, Winston-Salem, NC 27157, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5338-3979","authenticated-orcid":false,"given":"Alberto S.","family":"Pappo","sequence":"additional","affiliation":[{"name":"Department of Oncology, St. Jude Children\u2019s Research Hospital, Memphis, TN 38105, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8494-8031","authenticated-orcid":false,"given":"Andrew","family":"Elliott","sequence":"additional","affiliation":[{"name":"Caris Life Sciences, Phoenix, AZ 85040, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6419-2513","authenticated-orcid":false,"given":"Matthew J.","family":"Oberley","sequence":"additional","affiliation":[{"name":"Caris Life Sciences, Phoenix, AZ 85040, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9358-9843","authenticated-orcid":false,"given":"Mark G.","family":"Evans","sequence":"additional","affiliation":[{"name":"Caris Life Sciences, Phoenix, AZ 85040, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8515-2649","authenticated-orcid":false,"given":"Armita","family":"Bahrami","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA"},{"name":"Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/ng0298-184","article-title":"A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma","volume":"18","author":"Knezevich","year":"1998","journal-title":"Nat. Genet."},{"key":"ref_2","first-page":"5046","article-title":"ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma","volume":"58","author":"Knezevich","year":"1998","journal-title":"Cancer Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S1535-6108(02)00180-0","article-title":"Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma","volume":"2","author":"Tognon","year":"2002","journal-title":"Cancer Cell"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/PAS.0b013e3181d9efcc","article-title":"Mammary Analogue Secretory Carcinoma of Salivary Glands, Containing the ETV6-NTRK3 Fusion Gene: A Hitherto Undescribed Salivary Gland Tumor Entity","volume":"34","author":"Vanecek","year":"2010","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/PAS.0000000000001203","article-title":"Expanding the Spectrum of Pediatric NTRK-rearranged Mesenchymal Tumors","volume":"43","author":"Davis","year":"2019","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/gcc.22767","article-title":"The histologic spectrum of soft tissue spindle cell tumors with NTRK3 gene rearrangements","volume":"58","author":"Suurmeijer","year":"2019","journal-title":"Genes Chromosom. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.cancergen.2021.10.007","article-title":"NTRK-Rearranged soft tissue neoplasms: A review of evolving diagnostic entities and algorithmic detection methods","volume":"260\u2013261","author":"Surrey","year":"2022","journal-title":"Cancer Genet."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41379-020-0623-z","article-title":"Mesenchymal tumors of the gastrointestinal tract with NTRK rearrangements: A clinicopathological, immunophenotypic, and molecular study of eight cases, emphasizing their distinction from gastrointestinal stromal tumor (GIST)","volume":"34","author":"Atiq","year":"2020","journal-title":"Mod. Pathol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1158\/0008-5472.CAN-19-0372","article-title":"Detection of NTRK Fusions: Merits and Limitations of Current Diagnostic Platforms","volume":"79","author":"Solomon","year":"2019","journal-title":"Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1097\/PAS.0000000000000675","article-title":"Recurrent NTRK1 Gene Fusions Define a Novel Subset of Locally Aggressive Lipofibromatosis-like Neural Tumors","volume":"40","author":"Agaram","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/gcc.22846","article-title":"Emerging soft tissue tumors with kinase fusions: An overview of the recent literature with an emphasis on diagnostic criteria","volume":"59","author":"Antonescu","year":"2020","journal-title":"Genes Chromosom. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"101202","DOI":"10.1016\/j.esmoop.2023.101202","article-title":"Natural history and treatment efficacy in an ambispective case series of NTRK-rearranged mesenchymal tumors","volume":"8","author":"Dufresne","year":"2023","journal-title":"ESMO Open"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/s41379-021-01005-3","article-title":"Adult NTRK-rearranged spindle cell neoplasms of the viscera: With an emphasis on rare locations and heterologous elements","volume":"35","author":"Tsai","year":"2022","journal-title":"Mod. Pathol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1097\/PAS.0000000000001929","article-title":"NTRK -Rearranged Uterine Sarcomas: Clinicopathologic Features of 15 Cases, Literature Review, and Risk Stratification","volume":"46","author":"Costigan","year":"2022","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1097\/PAS.0000000000001055","article-title":"NTRK Fusions Define a Novel Uterine Sarcoma Subtype with Features of Fibrosarcoma","volume":"42","author":"Chiang","year":"2018","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1038\/s41379-018-0184-6","article-title":"Uterine and vaginal sarcomas resembling fibrosarcoma: A clinicopathological and molecular analysis of 13 cases showing common NTRK-rearrangements and the description of a COL1A1-PDGFB fusion novel to uterine neoplasms","volume":"32","author":"Croce","year":"2019","journal-title":"Mod. Pathol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of Larotrectinib in TRK Fusion\u2013Positive Cancers in Adults and Children","volume":"378","author":"Drilon","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: A pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Iannantuono, G.M., Riondino, S., Sganga, S., Rosenfeld, R., Guerriero, S., Carlucci, M., Capotondi, B., Torino, F., and Roselli, M. (2022). NTRK Gene Fusions in Solid Tumors and TRK Inhibitors: A Systematic Review of Case Reports and Case Series. J. Pers. Med., 12.","DOI":"10.3390\/jpm12111819"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1002\/cncr.35036","article-title":"Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas","volume":"129","author":"Kummar","year":"2023","journal-title":"Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nmeth.4197","article-title":"Salmon provides fast and bias-aware quantification of transcript expression","volume":"14","author":"Patro","year":"2017","journal-title":"Nat. Methods"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: Ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2012","journal-title":"Bioinformatics"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: Prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e000147","DOI":"10.1136\/jitc-2019-000147","article-title":"Establishing guidelines to harmonize tumor mutational burden (TMB): In silico assessment of variation in TMB quantification across diagnostic platforms: Phase I of the Friends of Cancer Research TMB Harmonization Project","volume":"8","author":"Merino","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1158\/1078-0432.CCR-20-3286","article-title":"Clinical Validation of a Machine-learning-derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer","volume":"27","author":"Abraham","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Siozopoulou, V., Smits, E., De Winne, K., Marcq, E., and Pauwels, P. (2021). NTRK Fusions in Sarcomas: Diagnostic Challenges and Clinical Aspects. Diagnostics, 11.","DOI":"10.3390\/diagnostics11030478"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.jmoldx.2019.03.008","article-title":"Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy","volume":"21","author":"Hsiao","year":"2019","journal-title":"J. Mol. Diagn."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/gcc.22671","article-title":"A novel group of spindle cell tumors defined by S100 and CD34 co-expression shows recurrent fusions involving RAF1, BRAF, and NTRK1\/2 genes","volume":"57","author":"Suurmeijer","year":"2018","journal-title":"Genes Chromosom. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/path.6260","article-title":"Comprehensive clinicopathological, molecular, and methylation analysis of mesenchymal tumors with NTRK and other kinase gene aberrations","volume":"263","author":"Dermawan","year":"2024","journal-title":"J. Pathol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/path.6341","article-title":"TRKing down drug resistance in NTRK fusion-positive cancers\u2020","volume":"264","author":"Parrish","year":"2024","journal-title":"J. Pathol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/2159-8290.CD-16-1237","article-title":"Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"viii23","DOI":"10.1093\/annonc\/mdz282","article-title":"TRK inhibitors in TRK fusion-positive cancers","volume":"30","author":"Drilon","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13000-023-01400-1","article-title":"Identification of dual STRN-NTRK2 rearrangements in a high grade sarcoma, with good clinical response to first-line larotrectinib therapy","volume":"18","author":"Lin","year":"2023","journal-title":"Diagn. Pathol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1021\/acs.biochem.9b00126","article-title":"Larotrectinib in NTRK-Rearranged Solid Tumors(Published as part of the Biochemistry series \u201cBiochemistry to Bedside\u201d)","volume":"58","author":"Wilson","year":"2019","journal-title":"Biochemistry"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41698-021-00206-y","article-title":"Genomic context of NTRK1\/2\/3 fusion-positive tumours from a large real-world population","volume":"5","author":"Westphalen","year":"2021","journal-title":"npj Precis. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/15\/2528\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T15:53:28Z","timestamp":1786031608000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/15\/2528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":36,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["cancers18152528"],"URL":"https:\/\/doi.org\/10.3390\/cancers18152528","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]}}}